Original ArticlesTherapeutic Options for the Treatment of Coronavirus Disease (COVID-19)Snawerdt, Jessica PharmD; Finoli, Lauren PharmD, BCPS, BCCCP; Bremmer, Derek N. PharmD, BCPS-AQ ID; Cheema, Tariq MD, FCCP, MMM; Bhanot, Nitin MD, MPH, FIDSAAuthor Information Department of Pharmacy (Drs Snawerdt, Finoli, and Bremmer), Division of Pulmonary Critical Care (Dr Cheema), and Division of Infectious Disease (Dr Bhanot) Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania. Correspondence: Nitin Bhanot, MD, MPH, FIDSA, Division of Infectious Disease, Allegheny General Hospital, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212 ([email protected]). Tariq Cheema serves on speaker's bureau for Glaxo-SmithKline and Boehringer Ingelheim, GSK. Nitin Bhanot received one time honorarium to attend an advisory meeting by MicrogenDx company. All other authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Critical Care Nursing Quarterly: October/December 2020 - Volume 43 - Issue 4 - p 349-368 doi: 10.1097/CNQ.0000000000000321 Buy Metrics Abstract Coronavirus disease 2019 (COVID-19) has resulted in an unprecedented pandemic, challenging practitioners to identify safe and effective therapeutic options in a limited amount of time. The rapid genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided a significant number of therapeutic targets. Repurposed and investigational agents are being studied for use in COVID-19. Although knowledge is rapidly expanding in regard to COVID-19 and there is promise with a few agents, there are no definitely proven effective therapies at this time. Supportive care remains the mainstay of therapy while ongoing clinical trials are being conducted. © 2020 Wolters Kluwer Health, Inc. All rights reserved.